Sort
48,018 grants matching “immunotherapy”
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
$642,253Linghua Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
$642,253Linghua Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Clearing Persistently HIV-Infected CD4+ T Lymphocytes
$642,138David M. Margolis · Univ Of North Carolina Chapel Hill · R01 · FY2007 · AI
E7 TCR-T cell therapy for HPV-associated cancers
$642,086Christian Hinrichs · Rutgers Biomedical And Health Sciences · U01 · FY2024 · CA
Guinea pig model for TB vaccine evaluations
$642,082Ian M Orme · Colorado State University · R01 · FY2006 · AI
SUPERCOOLED EX-VIVO PORCINE VCA PRESERVATION TO EXTEND THE TIMELINE BETWEEN PROCUREMENT AND TRANSPLANTATION AND ENABLE TOLERANCE INDUCTION TOELIMINATE IMMUNOTHERAPY NEEDS AND RISKS
$642,000The General Hospital Corporation · · FY2019 · Defense Health Agency
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$641,997Katerina Abigail Politi · Yale University · R01 · FY2023 · CA
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer Therapy
$641,994Eric C. Frey · Johns Hopkins University · U01 · FY2014 · CA
Processed Antigen Characterization by Mass Spectrometry
$641,956Donald F Hunt · University Of Virginia · R01 · FY2014 · AI
CAR neutrophils produced in vivo to remodel tumor microenvironment and treat glioblastoma
$641,936Xiaoping Bao · Purdue University · R01 · FY2025 · CA
TrialNet: DiabetesType 1 Prevention Trial
$641,905University Of Colorado Denver · U01 · FY2001 · DK
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
$641,858David M. Lewinsohn · Oregon Health & Science University · R01 · FY2019 · AI
Regulatory T Cell Function in Ovarian Cancer
$641,563Kirsten B Moysich · Roswell Park Cancer Institute Corp · R01 · FY2011 · CA
Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma
$641,534Richard Leo Wahl · Washington University · R01 · FY2025 · CA
Neural response to inflammatory challenge in major depressive disorder
$641,500Jonathan Savitz · Laureate Institute For Brain Research · R01 · FY2023 · MH
Imaging Modulation of Immune Phenotype
$641,412Katherine W Ferrara · Stanford University · R01 · FY2022 · CA
Imaging Modulation of Immune Phenotype
$641,412Katherine W Ferrara · Stanford University · R01 · FY2023 · CA
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer
$641,336Zihai Li · Ohio State University · R01 · FY2024 · CA
Targeting Aldehyde Dehydrogenase for Cancer Prevention
$641,281Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2020 · CA
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer
$641,281Dohun Pyeon · Michigan State University · R01 · FY2022 · DE
Three-dimensional conformation changes associated with T cell memory and autoimmunity
$641,265Raymond David Hawkins · University Of Washington · U01 · FY2024 · DK
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
$641,257Joseph John Barchi · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Resistance mechanisms to autophagy-modulating therapies
$641,245Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2023 · CA
Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy
$641,130Dan Landau · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS
$641,128University Of Southern California · R01 · FY2000 · NS